Cyagen Collaborated with Neurophth to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders
Shots:
- The companies collaborated to co-develop AAV gene therapy vectors for specific types of genetic ophthalmic disorders using Cyagen’s AI-powered high-throughput platform with optimized tissue targeting capability, tissue specificity & productivity. Cyage will receive milestones for the research & clinical phases along with sales royalties that could be worth ~$140M
- Both companies will lead the functional properties of AAV vectors in rodent & NHP models. Neurophth will lead to conducting the clinical trials & commercialization for gene therapy products using novel AAV capsids
- As compared to traditional directed evolution methods, Cyagen has created significant experimental data for AI model training & ML
Ref: PRNewswire | Image: Cyagen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
